Professor Farhad KamaliProf of Human & Exp Pharm
Email: farhad.kamali@ncl.ac.uk Telephone: +44 (0) 191 222 8043 Address: Institute of Cellular Medicine
Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur APA, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Körtke H, Levi M, Matchar D, Menéndez-Jándula B, Rakovac I, Schaefer C, Siebenhofer-Kroitzsch A, Souto JC, Sunderji R, Gin G, Shalansky K, Völler H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data .
Lancet 2012, 379 (9813), 322-334.
Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors .
British Journal of Clinical Pharmacology 2012, 73 (1), 66-76.
Biss TT, Avery PJ, Walsh PM, Kamali F. Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal] .
Journal of Thrombosis and Haemostasis 2011, 9 (11), 2332-2333.
Fairbairn-Smith L, Cope W, Robinson B, Kamali F, Wynne H. Effect of provision of the NHS NPSA oral anticoagulant therapy patient information pack upon patients' knowledge and anticoagulant control .
Journal of Thrombosis and Haemostasis 2011, 9 (1), 231-233.
Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F, on behalf of the EU-PACT Study Group. Proposal for an individualised pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy .
Clinical Pharmacology and Therapeutics 2011, 90 (5), 701-706.
Biss TT, Adamson AJ, Seal CJ, Kamali F. The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin .
Pediatric Hematology and Oncology 2011, 28 (5), 425-427.
Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children .
Blood 2011, 119 (3), 868-873.
Biss TT, Avery PJ, Walsh PM, Kamali F. Warfarin treatment outcomes in children monitored at home with a point-of-care device .
Thrombosis and Haemostasis 2011, 105 (6), 1103-1105.
Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Sarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, on behalf of the International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups .
Blood 2010, 115 (18), 3827-3834.
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation .
Thrombosis and Haemostasis 2005, 93 (5), 872-875.
Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin .
Clinical Pharmacology and Therapeutics 2004,75 3 204-212.
Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. The effect of dietary vitamin K upon intra-individual variability in anticoagulantion response to warfarin. .124 , 348-354.
Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation .
British Journal of Haematology 2004,126 4 557-564.
King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism .
Pharmacogenetics 2004,14 12 813-822.
Kamali F. [Book Review] Introduction to drug metabolism .
British Journal of Clinical Pharmacology 2003, 56 (3), 345.
King BP, Khan T, Kamali F, Daly AK. Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements .
In: Drug Metabolism Reviews: 8th European Meeting of the International Society for the Study of Xenobiotics (ISSX) . 2003, Dijon, France: Informa Healthcare.
Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements .89 5 949-950.
Jaffary F, Khan T, Wynne HA, Kesteven PJ, Kamali F. The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life .
Journal of the American Geriatrics Society 2003,51 6 885-887.
Khan T, Kamali F, Daly A, King B, Wynne HA. Warfarin sensitivity: Be aware of genetic influence .
Age and Ageing 2003,32 2 226-227.
Siccardi D, Kamali F. Stereoselectivity in thioridazine metabolism in vitro .
British Journal of Clinical Pharmacology 2002, 53 (4), 445P.
Newbury-Birch D, Lowry RJ, Kamali F. The changing pattern of drinking, illicit drug use, stress, anxiety and depression in dental students: a longitudinal study (authors reply) .
British Dental Journal 2002, 193 (5), 244.
Webb J, Rostami-Hodjegan A, Abdul-Manap R, Mikus G, Hofman U, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a Pk-PD modelling analysis .
British Journal of Clinical Pharmacology 2001, 52 (1), 35-43.
Newbury-Birch D, Walshaw D, Kamali F. Drink and drugs: From medical students to doctors .
Drug and Alcohol Dependence 2001, 64 (3), 265-270.
Kamali F. Osanetant Sanofi-Synthélabo .
Current Opinion in Investigational Drugs 2001, 2 (7), 950-956.
Newbury-Birch D, Kamali F. Psychological stress, anxiety, depression, job satisfaction, and personality characteristics in preregistration house officers .
Postgraduate Medical Journal 2001, 77 (904), 109-111.
Kamali F, Edwards C, Wood P, Wynne HA, Kesteven P. Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans .
American Journal of Hematology 2001, 68 (3), 159-163.
Kamali F. Almotriptan Almirall Prodesfarma SA .
Current Opinion in CPNS Investigational Drugs 2000, 2 , 197-202.
Kamali F. Apomorphine, sublingual (TAP Pharmaceuticals) .
Current Opinion in Central and Peripheral Nervous System Investigational Drugs 2000, 2 (3), 303-310.
Kamali F, Edwards C, Butler TJ, Wynne HA. The contribution of plasma (R)- and (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation .
Thrombosis and Haemostasis 2000, 83 (2), 349-350.
Kamali F, Edwards C, Butler TJ, Wynne HA. The influence of (R)- and (S)-Warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation .
Thrombosis and Haemostasis 2000, 84 (1), 39-42.
Kamali F. BMS-181885-Bristol Myers Squibb .
Current Opinions in CPNS Investigational Drugs 1999, 1 , 98-101.
Kamali F. Ditropan XL ALZA Corp .
IDrugs 1999, 2 (4), 360-365.
Kamali F. Ditropan-XL-Alza Corp .
Current Opinions in CPNS Investigational Drugs 1999, 1 , 278-283.
Kamali F. KMD-3213-Kissei Pharmaceutical Co Ltd .
Current Opinions in CPNS Investigational Drugs 1999, 1 , 248-252.
Kamali F. Rofecoxib- Merck & Co Inc .
Current Opinions in CPNS Investigational Drugs 1999, 1 , 126-131.
Kamali F. Talsaclidine fumarate-Boehringer Ingelheim Corp .
Current Opinions in CPNS Investigational Drugs 1999, 1 , 373-377.
Kamali F, Ball DE, Mcloughlin WS and Seymour RA. The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth .
J Clin Perio 1999, 26 , 802-805.
Birch D, Ashton H, Kamali F. Alcohol drinking, illicit drug use and stress in junior house officers in the north east of England .
Lancet 1998, 352 , 785-786.
Webb E, Ashton CH, Kelly P, Kamali F. Alcohol and drug use in UK university students .
Lancet 1996, 384 , 922-925.
